GSK’s Promacta deadline also expires
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
GlaxoSmithKline's PDUFA date also came and went Sept. 19 for Promacta, though not because of strained resources; the missed deadline for eltrombopag is presumably because FDA and GSK are fine-tuning a Risk Evaluation and Mitigation Strategy for the novel drug candidate to treat chronic immune thrombocytopenic purpura (1"The Pink Sheet" DAILY, Sept. 22, 2008). Amgen's NPlate, also indicated for thrombocytopenia, had a similar delay while the REMS was finalized. Analysts said that the missed user fee date was good news for GSK because if the agency had serious concerns it most likely would have issued a complete response letter and not delayed a decision. In May, Promacta received a positive review from the Oncologic Drugs Advisory Committee as a second-line, short-term treatment for ITP, but the panel had reservations about whether the drug would be used for longer term off-label
You may also be interested in...
REMS Likely Holdup For GSK’s Promacta Approval
FDA misses eltrombopag Sept. 19 PDUFA date; analysts draw parallel with Amgen’s Nplate timeline.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.